Since the screen was performed in a lung cancer cell line, we analysed RNA-seq from 326 primary lung carcinoma (LUAD and LUSC) TP53 wild-type tumour samples and 108 healthy TP53 wild-type lung samples from TCGA database, in order to correlate the expression of candidate genes with alterations in the p53-downstream effectors (p53 pathway). The gene discussed is TP53; the disease is neoplasm.